Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

Azra Raza, Naomi Galili, Deborah Mulford, Scott E. Smith, Gail L. Brown, David P. Steensma, Roger M. Lyons, Ralph Boccia, Mikkael A. Sekeres, Guillermo Garcia-Manero, Ruben A. Mesa

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)'. Together they form a unique fingerprint.

Medicine & Life Sciences